PHGE Insider Trading

Insider Ownership Percentage: 4.21%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $4,038.18

BiomX Insider Trading History Chart

This chart shows the insider buying and selling history at BiomX by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

BiomX Share Price & Price History

Current Price: $0.35
Price Change: Price Decrease of -0.01 (-2.78%)
As of 05/29/2024 01:00 AM ET

This chart shows the closing price history over time for PHGE up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

BiomX Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/29/2023Assaf OroninsiderSell10,914$0.37$4,038.18View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for BiomX (NYSEAMERICAN:PHGE)

40.57% of BiomX stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

BiomX Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
2/12/2024MMCAP International Inc. SPC96,805$26K0.0%-81.1%0.211%Search for SEC Filing on Google Icon
2/12/20248VC GP I LLC1,086,191$0.30M0.3%N/A2.362%Search for SEC Filing on Google Icon
8/17/2020Jane Street Group LLC17,424$96K0.0%N/A0.076%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
BiomX logo
BiomX Inc., a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC). It is developing BX004, a phage therapy for CF patients with chronic Pseudomonas aeruginosa respiratory infections that is in Phase 1b/2a clinical trials. The company's pipeline products also include BX005, a topical phage cocktail, which is in Phase 1/2 clinical study that targets Staphylococcus aureus (S. aureus), a bacteria associated with the manifestation of the disease. In addition, the company engages in the provision of colorectal cancer program that utilizes engineered phage with various payloads, which are administered intravenously to target Fusobacterium nucleatum bacteria residing within the tumor microenvironment. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.
Read More on BiomX

Today's Range

Now: $0.35
Low: $0.35
High: $0.39

50 Day Range

MA: N/A

52 Week Range

Now: $0.35
Low: $0.19
High: $0.86

Volume

177,620 shs

Average Volume

1,674,349 shs

Market Capitalization

$24.43 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.31

Who are the company insiders with the largest holdings of BiomX?

BiomX's top insider investors include:
  1. Assaf Oron (Insider)
Learn More about top insider investors at BiomX.